Patents by Inventor Robertus Jacobus Maria Moormann
Robertus Jacobus Maria Moormann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9750798Abstract: The invention relates to a bunyavirus, in which separated (NSm)Gn and Gc coding regions are functionally present on two different genome segments, preferably a bunyavirus that comprises a total of at least 4 genome segments. The invention further relates to methods for producing said bunyavirus, and to a composition comprising said bunyavirus and a suitable excipient.Type: GrantFiled: May 21, 2014Date of Patent: September 5, 2017Assignee: STICHTING WAGENINGEN RESEARCHInventors: Jeroen Alexander Kortekaas, Paulus-Jozef Wichgers Schreur, Nadia Dimitrova Oreshkova, Robertus Jacobus Maria Moormann
-
Patent number: 9657278Abstract: The invention relates to methods of producing infectious bunyavirus replicon particles. These bunyavirus replicon particles are safe and can be used outside a biosafety containment. The invention further relates to recombinant bunyavirus replicon particles and uses of these recombinant bunyavirus replicon particles.Type: GrantFiled: July 10, 2015Date of Patent: May 23, 2017Assignee: Stichting Dienst Landbouwkundig OnderzoekInventors: Jeroen Alexander Kortekaas, Robertus Jacobus Maria Moormann
-
Publication number: 20160271241Abstract: The invention relates to a bunyavirus, in which separated (NSm)Gn and Gc coding regions are functionally present on two different genome segments, preferably a bunyavirus that comprises a total of at least 4 genome segments. The invention further relates to methods for producing said bunyavirus, and to a composition comprising said bunyavirus and a suitable excipient.Type: ApplicationFiled: May 21, 2014Publication date: September 22, 2016Applicant: Stichting Dienst Landbouwkundig OnderzoekInventors: Jeroen Alexander Kortekaas, Paulus-Jozef Wichgers Schreur, Nadia Dimitrova Oreshkova, Robertus Jacobus Maria Moormann
-
Publication number: 20160002608Abstract: The invention relates to methods of producing infectious bunyavirus replicon particles. These bunyavirus replicon particles are safe and can be used outside a biosafety containment. The invention further relates to recombinant bunyavirus replicon particles and uses of these recombinant bunyavirus replicon particles.Type: ApplicationFiled: July 10, 2015Publication date: January 7, 2016Inventors: Jeroen Alexander Kortekaas, Robertus Jacobus Maria Moormann
-
Patent number: 9109199Abstract: The invention relates to methods of producing infectious bunyavirus replicon particles. These bunyavirus replicon particles are safe and can be used outside a biosafety containment. The invention further relates to recombinant bunyavirus replicon particles and uses of these recombinant bunyavirus replicon particles.Type: GrantFiled: September 20, 2011Date of Patent: August 18, 2015Assignee: STICHTING DIENST LANDBOUWKUNDIG ONDERZOEKInventors: Jeroen Alexander Kortekaas, Robertus Jacobus Maria Moormann
-
Publication number: 20130236493Abstract: The invention relates to methods of producing infectious bunyavirus replicon particles. These bunyavirus replicon particles are safe and can be used outside a biosafety containment. The invention further relates to recombinant bunyavirus replicon particles and uses of these recombinant bunyavirus replicon particles.Type: ApplicationFiled: September 20, 2011Publication date: September 12, 2013Applicant: STICHTING DIENST LANDBOUWKUNDIG ONDERZOEKInventors: Jeroen Alexander Kortekaas, Robertus Jacobus Maria Moormann
-
Publication number: 20120276139Abstract: The invention relates to methods of stimulating an immune response against an antigenic protein in a mammalian subject. More specifically, the invention relates to routes of administration of a hybrid Newcastle Disease Virus-vector (NDV-vector) for eliciting an immune response against an antigenic protein that is encoded by the hybrid NDV-vector.Type: ApplicationFiled: November 16, 2010Publication date: November 1, 2012Applicant: Stichting Dienst Landbouwkundig OnderzoekInventors: Robertus Jacobus Maria Moormann, Jeroen Alexander Kortekaas, Adrianus Franciscus Gerardus Antonis, Bernardus Petrus Hubertus Peeters, Aldo Dekker
-
Patent number: 7521058Abstract: The invention relates to vaccines used in the eradication or control of pestivirus infections, particularly those used in pigs or ruminants. The invention provides nucleic acid, pestivirus-like particles and a pestivirus vaccine, comprising the nucleic acid or particles, which is capable of eliciting a proper immune response without having the ability to spread throughout the vaccinated animal, thereby avoiding the negative consequences of viral spread. Preferably, the immune response allows for serological discrimination between vaccinated animals and wild-type pestivirus infected animals.Type: GrantFiled: March 21, 2005Date of Patent: April 21, 2009Assignee: ID-Lelystad, Instituut voor Dierhouderij en Diergezondheid B.V.Inventors: Myra Noorely Widjojoatmodjo, Robertus Jacobus Maria Moormann, Petrus Antonius van Rijn
-
Patent number: 7335473Abstract: Composition of matter comprising the causative agent of Mystery Swine Disease, Lelystad Agent, in a live, attenuated, dead, or recombinant form, or a part or component of it. Vaccine compositions and diagnostic kits based thereon. Recombinant nucleic acid comprising a Lelystad Agent-specific nucleotide sequence. Peptides comprising a Lelystad Agent-specific amino acid sequence. Lelystad Agent-specific antibodies.Type: GrantFiled: July 14, 2004Date of Patent: February 26, 2008Assignee: Boehringer Ingelheim Vetmedica GmbHInventors: Gert Wensvoort, Catharinus Terpstra, Joannes Maria Anthonis Pol, Robertus Jacobus Maria Moormann, Johanna Jacoba Maria Meulenberg
-
Patent number: 6923969Abstract: The invention relates to vaccines used in the eradication or control of pestivirus infections, particularly used in pigs or ruminants. The invention provides nucleic acid, pestivirus-like particles and a pestivirus vaccine, comprising the nucleic acid or particles, which is capable of eliciting a proper immune response without having the ability to spread throughout the vaccinated animal, thereby avoiding the negative consequences of viral spread. Preferably, the immunological response allows for serological discrimination between vaccinated animals and wild-type pestivirus infected animals.Type: GrantFiled: September 7, 2001Date of Patent: August 2, 2005Assignee: ID-Lelystad, Instituut voor Dierhouderij en Diergezondheid B.V.Inventors: Myra N. Widjojoatmodjo, Robertus Jacobus Maria Moormann, Petrus Antonius Van Rijn
-
Patent number: 6919085Abstract: The invention relates to a method of increasing protein expression in baculo vector virus expression systems. The invention provides a method to produce a recombinant protein in insect cell culture which comprises selecting a recombinant baculovirus expressing said protein, growing insect cells in growth medium in a culture vessel and infecting the cells with an inoculum of at least one baculovirus at a cell density of 1×105 to 5×106 cells/ml with an m.o.i of <0.01. The invention also provides a method to produce recombinant pestivirus E2 or Em9 protein or fragments thereof in insect cell culture characterized by a final concentration of the protein fragments in the growth medium at harvest of at least 100 ?g/ml. The invention also provides a method of producing recombinant FSH, ?-units and/or ?-units, and complexes and fragments thereof, at a concentration in the growth medium at harvest of at least 15 ?/ml.Type: GrantFiled: February 27, 2003Date of Patent: July 19, 2005Assignees: Stichting Instituut voor Dierhouderij en Diergezondheid, Bayer AGInventors: Dietmar Kretzdorn, Dirk Franciscus Marinus van de Wiel, Abraham Johannes de Smit, Robertus Jacobus Maria Moormann, Erik Kees Hamann
-
Patent number: 6806086Abstract: Composition of matter comprising the causative agent of Mystery Swine Disease, Lelystad Agent, in a live, attenuated, dead, or recombinant form, or a part or component of it. Vaccine compositions and diagnostic kits based thereon. Recombinant nucleic acid comprising a Lelystad Agent-specific nucleotide sequence. Peptides comprising a Lelystad Agent-specific amino acid sequence. Lelystad Agent-specific antibodies.Type: GrantFiled: August 21, 2002Date of Patent: October 19, 2004Assignee: Stichting Centraal Diergeneeskundig InstituutInventors: Gert Wensvoort, Catharinus Terpstra, Joannes Maria Anthonis Pol, Robertus Jacobus Maria Moormann, Johanna Jacoba Maria Meulenberg
-
Publication number: 20040132014Abstract: Composition of matter comprising the causative agent of Mystery Swine Disease, Lelystad Agent, in a live, attenuated, dead, or recombinant form, or a part or component of it. Vaccine compositions and diagnostic kits based thereon. Recombinant nucleic acid comprising a Lelystad Agent-specific nucleotide sequence. Peptides comprising a Lelystad Agent-specific amino acid sequence. Lelystad Agent-specific antibodies.Type: ApplicationFiled: December 16, 2003Publication date: July 8, 2004Inventors: Gert Wensvoort, Catharinus Terpstra, Joannes Maria Anthonis Pol, Robertus Jacobus Maria Moormann, Johanna Jacoba Maria Meulenberg
-
Publication number: 20040028701Abstract: The invention relates to a method of increasing protein expression in baculo vector virus expression systems. The invention provides a method to produce a recombinant protein in insect cell culture which comprises selecting a recombinant baculovirus expressing said protein, growing insect cells in growth medium in a culture vessel and infecting the cells with an inoculum of at least one baculovirus at a cell density of 1×105 to 5×106 cells/ml with an m.o.i of <0.01. The invention also provides a method to produce recombinant pestivirus E2 or Em9 protein or fragments thereof in insect cell culture characterized by a final concentration of the protein fragments in the growth medium at harvest of at least 100 &mgr;g/ml. The invention also provides a method of producing recombinant FSH, &agr;-units and/or &bgr;-units, and complexes and fragments thereof, at a concentration in the growth medium at harvest of at least 15 &mgr;/ml.Type: ApplicationFiled: February 27, 2003Publication date: February 12, 2004Inventors: Dietmar Kretzdorn, Dirk Franciscus Marinus van de Wiel, Abraham Johannes de Smit, Robertus Jacobus Maria Moormann, Erik Kees Hamann
-
Publication number: 20030118608Abstract: Composition of matter comprising the causative agent of Mystery Swine Disease, Lelystad Agent, in a live, attenuated, dead, or recombinant form, or a part or component of it. Vaccine compositions and diagnostic kits based thereon. Recombinant nucleic acid comprising a Lelystad Agent-specific nucleotide sequence. Peptides comprising a Lelystad Agent-specific amino acid sequence. Lelystad Agent-specific antibodies.Type: ApplicationFiled: August 21, 2002Publication date: June 26, 2003Inventors: Gert Wensvoort, Catharinus Terpstra, Joannes Maria Anthonis Pol, Robertus Jacobus Maria Moormann, Johanna Jacoba Maria Meulenberg
-
Patent number: 6555346Abstract: The invention relates to a method to increase protein expression in baculo vector virus expression systems. The invention provides a method to produce a recombinant protein in insect-cell culture which comprises selecting a recombinant baculovirus expressing said protein, growing insect cells in growth medium in a culture vessel and infecting the cells with an inoculum of at least one baculovirus at a cell density of 1×105 to 5×106 cells/ml with an m.o.i of <0.01. The invention furthermore provides a method to produce recombinant pestivirus E2 or Em9 protein or fragments thereof in insect cell culture characterized by a final concentration of said protein (fragments) in the growth medium at harvest of at least 100 &mgr;g/ml. The invention furthermore provides a method to produce recombinant follicle stimulating hormone, &agr;-units an/or &bgr;-units and complexes and fragments thereof, at a concentration in the growth medium at harvest of at least 15 &mgr;l.Type: GrantFiled: June 16, 2000Date of Patent: April 29, 2003Assignees: Stichting Instituut voor Dierhouderij en Diergezondheid, Bayer AGInventors: Dietmar Kretzdorn, Dirk Franciscus Marinus van de Wiel, Abraham Johannes de Smit, Robertus Jacobus Maria Moormann, Erik Kees Hamann
-
Patent number: 6455245Abstract: Composition of matter comprising the causative agent of Mystery Swine Disease, Lelystad Agent, in a live, attenuated, dead, or recombinant form, or a part or component of it. Vaccine compositions and diagnostic kits based thereon. Recombinant nucleic acid comprising a Lelystad Agent-specific nucleotide sequence. Peptides comprising a Lelystad Agent-specific amino acid sequence. Lelystad Agent-specific antibodies.Type: GrantFiled: May 5, 2000Date of Patent: September 24, 2002Assignee: Stichting Centraal Diergeneeskundig InstituutInventors: Gert Wensvoort, Catharinus Terpstra, Joannes Maria Anthonis Pol, Robertus Jacobus Maria Moormann, Johanna Jacoba Maria Meulenberg
-
Patent number: 6183987Abstract: The invention provides methods for the production of recombinant bovine Follicle Stimulating Hormone (bFSH) as well as vectors and cells for use in those methods. In particular the invention provides baculovirus based vectors which are capable of expression of bFSH in insect cells. bFSH is a heterodimeric protein belonging to a family of glycoprotein hormones which are produced in the pituitary or the placenta. It finds its use in many fertility related applications. Expression of bFSH in baculovirus/insect cell systems leads to a recombinant bFSH which has an unexpected high activity in a human FSH receptor assay and/or a bovine immature oocyte assay. The genes encoding the subunits of bFSH may be present on one baculovirus derived vector or on two or more vectors which are to be cotransfected.Type: GrantFiled: November 12, 1997Date of Patent: February 6, 2001Assignee: Stichting Institut voor Dierhouderij en DiergezonheldInventors: Dirk Franciscus Marinus van de Wiel, Petrus Antonius van Rijn, Robertus Jacobus Maria Moormann, Robert Hans Meloen
-
Patent number: 6180109Abstract: The invention provides a nucleotide sequence corresponding to a classical swine fever virus (CSFV) genome or a part or a mutant thereof, which comprises at least a part of the nucleotide sequence of the CSFV C-strain depicted in SEQ ID No. 1, or a complement or RNA equivalent of such nucleotide sequence, or which comprises a nucleotide sequence encoding at least the amino acid sequence 268-494 of the amino acid sequence depicted in SEQ ID No. 1, or a complement or RNA equivalent of such nucleotide sequence. Also provided is a pestivirus polypeptide corresponding to the amino acid sequence 690-1063 of SEQ ID No. 1 or part thereof, which contains a mutation in one of the epitopes within amino acid sequences 691-750 or 785-870, said mutation altering said epitope.Type: GrantFiled: December 24, 1996Date of Patent: January 30, 2001Assignee: Instituut Voor Dierhouderij en DiergezondheidInventors: Robertus Jacobus Maria Moormann, Petrus Antonius Van Rijn
-
Patent number: 5674500Abstract: The invention provides vaccines for preventing and controlling animal diseases, comprising a pseudorabies virus containing glycoprotein gp50 and having a mutation in its gp50 gene. The vaccines are suitable for use against Aujeszky's disease (pseudorabies), or against other animal diseases when the mutation is an insertion comprising a heterologous gene encoding an antigen corresponding to said animal disease. The pseudorabies virus may additionally have at least one mutation in one of its other genes, such as the gp63 gene or the gI gene. The vaccines are unable to spread from vaccinated to non-vaccinated animals.Type: GrantFiled: January 9, 1995Date of Patent: October 7, 1997Assignee: Akzo Nobel N.V.Inventors: Bernardus Petrus Hubertus Peeters, Jan Marie Antonius Pol, Arnold Leonard Josef Gielkens, Robertus Jacobus Maria Moormann